Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{3-[4-(3-amino-propyl)-piperazin-1-yl]-propyl}-3-nitro-5-(galactopyranosyl)-beta-benzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule glycoside derivative designed as an experimental inhibitor of the cholera toxin B subunit (CTB). It features a galactopyranoside moiety linked to a nitrobenzamide core and a piperazine side chain. The compound was developed as part of structure-based drug design efforts to block the binding of cholera toxin to its GM1 ganglioside receptor on host cells. Structural studies have shown that it binds in the GM1 binding pocket of CTB and acts as an antagonist by preventing toxin attachment and subsequent cell entry. It has demonstrated improved affinity over earlier m-nitrophenyl-galactopyranoside derivatives in crystallographic studies but has not advanced into clinical development or received regulatory approval[5][9].
- Other names
- N-(3-(4-(3-amino-propyl)-piperazin-1-yl)-propyl)-3-nitro-5-(galactopyranosyl)-beta-benzamideN-{3-[4-(3-AMINO-PROPYL)-PIPERAZIN-1-YL]-PROPYL}-3-NITRO-5-(GALACTOPYRANOSYL)-BETA-BENZAMIDEN-{3-[4-(3-Aminopropyl)piperazin-1-y]propyl}-3-nitro-5-{[(2S,3R,4S,5R,6R)-trihydroxyhexanoyl]oxy}benzamide
02
Targets
CTBS (Cholera toxin B subunit)
Beyond the preview
Go deeper on N-{3-[4-(3-amino-propyl)-piperazin-1-yl]-propyl}-3-nitro-5-(galactopyranosyl)-beta-benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-{3-[4-(3-amino-propyl)-piperazin-1-yl]-propyl}-3-nitro-5-(galactopyranosyl)-beta-benzamide.